<DOC>
	<DOCNO>NCT00998699</DOCNO>
	<brief_summary>The study hypothesis XOMA 052 may inhibit beta-cell destruction enhance beta-cell regeneration . The purpose study assess effect XOMA 052 beta-cell function insulin production .</brief_summary>
	<brief_title>Study Effects XOMA 052 Insulin Production Subjects With Well Controlled Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Inclusion criterion : Stable Type 1 diabetes &gt; 2 year duration No clinically significant change treatment regimen T1D Age ≥ 18 year ≤ 55 year HbA1c &lt; 7.0 % Positive GAD65 and/or IA2 autoantibodies Peak Cpeptide &gt; 100 pM follow IV injection 1 mg glucagon Bodymass index ( BMI ) &gt; 18 &lt; 28 kg/m2 Willingness maintain current doses/regimens vitamin dietary supplement end study Exclusion criterion : Current infection history infection Positive Hep B surface antigen ( HBsAg ) , Hep C virus ( HCV ) , HIV History tuberculosis positive PPD test Presence foot , leg , decubitus ulcer Current immunosuppressive treatment document immunodeficiency History severe allergic anaphylactic reaction History asthma require systemic corticosteroid therapy Coronary intervention ( PCI , stent placement ) hospitalization cardiovascular condition within last 12 month Uncontrolled hypertension History congestive heart failure ( NYHA Class III IV ) History coronary event within last 12 month Female subject pregnant , plan become pregnant , recently deliver , breastfeed History malignancy within last 5 year Receipt live ( attenuate ) vaccine within last 3 month Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Type 1</keyword>
</DOC>